Porvair’s membrane filters ensure higher flow rates
Designed to withstand pressure during filtration
The rigorous construction of these pleated membrane cartridges ensures higher flow rates, lower pressure differentials and faster process times, the company says. Independently verified to meet USP Class VI and ISO 10993, each filter is provided with a certificate of quality. Manufacturing takes place in an ISO Class 5 cleanroom in accordance with accredited quality procedures and the membrane is protected from damage during production by the inner and outer drainage layers that maintain the pleat pack structure.
The filter's inner core comprises a thermoplastic material that further supports the pleat pack and draws the filtrate through its perforations to the outlet of the cartridge. Snugly encased in a polymeric outer cage and securely fitted with sanitary design adaptors that provide optimal sealing and safety against bypass, each cartridge is identified by a serial number embossed on the outer sleeve, providing full traceability to all FDA CFR 21 and EC-approved manufacturing components.
The supply chain is closely monitored with in-house production of the filter’s outer cage, core and end cap. Careful attention to package design minimises the chance of damage to the filters during transit and storage, says Porvair.
Assurance of the high quality of Porvair membrane cartridge filters is further demonstrated by post-manufacture integrity testing, which is a non-destructive means of determining oversized pores or defects.
The integrity test parameters employed by Porvair are correlated to the filter's microbial retention capabilities as determined during validation in accordance with ASTM F838-05, HIMA and PDA Technical Reports 26 and 40. Any filter that fails integrity testing is immediately discarded.
Porvair Filtration Group is an international leader in the development and supply of materials and products for applications in filtration and separation. It has offices and manufacturing sites in the UK, Europe and the US and a worldwide network of distributors.
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
Read moreAt Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Trending Articles
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
At Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing
BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany
The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology